中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (10): 2093-2094.doi: 10.4103/1673-5374.392860

• 观点:脑损伤修复保护与再生 •    下一篇

P75神经营养因子受体调节减轻小鼠缺血性脑卒中后的脑损伤

  

  • 出版日期:2024-10-15 发布日期:2024-01-29

Modulation of p75 neurotrophin receptor mitigates brain damage following ischemic stroke in mice

Golnoush Mirzahosseini, Tauheed Ishrat*#br#   

  1. Department of Anatomy and Neurobiology, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN, USA (Mirzahosseini G, Ishrat T)
    Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN, USA (Mirzahosseini G, Ishrat T)
    Neuroscience Institute, The University of Tennessee Health Science Center, Memphis, TN, USA (Ishrat T)
  • Online:2024-10-15 Published:2024-01-29
  • Contact: Tauheed Ishrat, PhD, tishrat@uthsc.edu.
  • Supported by:
    This work was supported by the UTHSC Bridge funding award (E073005058 Bridge Support-2022) and the National Institute of Health (R01-NS097800 and R56 NS127924-01) to TI.

摘要: https://orcid.org/0000-0002-9869-1342 (Tauheed Ishrat)

Abstract: Stroke is a significant leading cause of death and disability in the United States (Tsao et al., 2022). Approximately 87% of strokes fall into the ischemic category, mainly caused by arterial blockage (Jayaraj et al., 2019). Although the only FDA-approved effective medication is tissue plasminogen activator (tPA), it should be administrated within 4.5 hours of ischemic stroke. Furthermore, tPA has been an integral part of managing acute ischemic stroke. However, it increases the development of intracerebral hemorrhage (Goncalves et al., 2022). Therefore, discovering a novel neuroprotective drug is a high clinical need. In recent years, there has been a significant increase in the utilization of thrombectomy procedures.